Hepatitis B in Africa Collaborative Network: cohort profile and analysis of baseline data.
Hepatitis B in Africa Collaborative Network: cohort profile and analysis of baseline data.
复制标题
DOI：
10.1017/s095026882300050x
复制
发表时间：
2023-04-03
影响因子：
4.2
通讯作者：
Spearman, C. Wendy
中科院分区：
文献类型：
--
作者：
Riches, Nicholas;Vinikoor, Michael;Guingane, Alice;Johannessen, Asgeir;Lemoine, Maud;Matthews, Philippa;Okeke, Edith;Shimakawa, Yusuke;Sombie, Roger;Stockdale, Alexander;Wandeler, Gilles;Andersson, Monique;Davwar, Pantong;Desalegn, Hailemichael;Duguru, Mary;Fall, Fatou;Maponga, Tongai;Nyam Paul, David;Seydi, Moussa;Sinkala, Edford;Taljaard, Jantjie;Sonderup, Mark;Spearman, C. Wendy
世卫组织非洲区域约有8000万人感染慢性乙型肝炎病毒（HBV）。由于流行基因型、环境暴露、合并感染和宿主遗传的差异，该人群HBV感染的自然史特征不明确，可能与其他地方观察到的模式不同。现有的研究大多来自小规模的单中心队列，随访时间有限。非洲乙型肝炎合作网络（HEPSANET）成立于2022年，旨在协调来自8个非洲国家的13个合作HBV队列的持续数据收集、分析和传播过程。在进行基线数据分析之前，通过修改的德尔菲调查商定了未来5年的研究重点。收集了4173名慢性HBV单一感染参与者的基线数据，其中38.3%为女性，中位年龄为34岁（四分位数范围为28-42岁）。81.3%的病例是通过无症状个体检测发现的。9.6%的参与者呈hbeag阳性。HEPSANET参与者的随访将为改善该地区HBV的诊断和管理提供证据。
Approximately 80 million people live with chronic hepatitis B virus (HBV) infection in the WHO Africa Region. The natural history of HBV infection in this population is poorly characterised, and may differ from patterns observed elsewhere due to differences in prevailing genotypes, environmental exposures, co-infections, and host genetics. Existing research is largely drawn from small, single-centre cohorts, with limited follow-up time. The Hepatitis B in Africa Collaborative Network (HEPSANET) was established in 2022 to harmonise the process of ongoing data collection, analysis, and dissemination from 13 collaborating HBV cohorts in eight African countries. Research priorities for the next 5 years were agreed upon through a modified Delphi survey prior to baseline data analysis being conducted. Baseline data on 4,173 participants with chronic HBV mono-infection were collected, of whom 38.3% were women and the median age was 34 years (interquartile range 28–42). In total, 81.3% of cases were identified through testing of asymptomatic individuals. HBeAg-positivity was seen in 9.6% of participants. Follow-up of HEPSANET participants will generate evidence to improve the diagnosis and management of HBV in this region.